Kura Oncology, Inc. (KURA) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

12/25

Growth 4 Margin 2 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

12
KURA Oncology (KURA) Q2 2026: KOMZIFTI Sales Surge 57%, Cementing AML Market Leadership
August 13, 2026
12
Kura Oncology (KURA) Q1 2026: ComSifty Captures 40% New Patient Share, Accelerating Class Leadership
May 13, 2026
13
KURA Q4 2025: ComSifty Launch Drives $2.1M Revenue, Step-Edit Access Signals Class Leadership Shift
March 05, 2026
8
Kura Oncology (KURA) Q3 2025: $105M Milestone Inflow Accelerates Ziftomenib Launch Readiness
November 04, 2025
9
Kura Oncology (KURA) Q2 2025: $630M Cash Anchors Zipdementib Launch and Phase III Acceleration
August 08, 2025
8
Kura Oncology (KURA) Q1 2025: Cash Position Rises to $703M, Pipeline Momentum Sets Up Multi-Asset Inflection
July 04, 2025

Browse all companies